ArticleFrontiers in neurology2025
Perspective: Use of protein S100B as a quality assurance marker for endovascular therapy in acute ischemic stroke.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent advances in stroke biomarkers - implications for prognosis and treatment.Current opinion in neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mechanical thrombectomy (MT) is a highly effective treatment for ischemic stroke associated with large vessel occlusion. Given its complexity, this procedure is widely used throughout the world in hospitals with different levels of experience. Therefore, practical quality assurance is advised to ensure a high standard of care across the board. In this perspective article, we propose the implementation of measuring serum S100B after MT as a surrogate outcome parameter for the extent of tissue damage as an additional quality indicator for internal and external benchmarking in endovascular therapy. We focus on the analysis of patients, in whom there is a discrepancy between the expected (e.g., based on favorable preconditions) and the actual biomarker outcome. We aim to illustrate the advantages and drawbacks of measuring S100B after MT, reliably depicting the procedure's quality and its use for comparison and identification of "outlier" patients in MT patient cohorts for further process and single-case analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.